Previous studies have shown that FGF15 (FGF19 in human) can inhibit the expression of hepatic paraoxonase-1 (PON-1) in mice (36) and that human liver cancer cells treated with recombinant human FGF19 can inhibit the expression of PON-1 (37). Here, FGF19 is linked to liver cancer.